Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Geron Corporation's Stock Is Ripping Higher Today

By George Budwell - Sep 3, 2015 at 12:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geron Corp.'s stock jumped on the announcement that the New England Journal of Medicine published two papers today highlighting the unprecedented disease-modifying ability of its telomerase inhibitor imetelstat in two blood-based disorders.

What: Shares of the clinical-stage biotech Geron Corp. (GERN 0.77%) rose by as much as 20% today on sky-high volume after the company announced the publication of two papers in the The New England Journal of Medicine (NEJM) highlighting the potentially disease-modifying ability of its telomerase inhibitor imetelstat in essential thrombocythemia (ET) and myelofibrosis (MF).

In a midstage study for MF, for example, the therapy led to some form of response in every patient receiving imetelstat, with several experiencing complete hematological responses. The papers were published online this morning via the journal's website, according to the company. 

So whatIncyte and Novartis' Jakafi is the only drug approved by the Food and Drug Administration for the treatment of myelofibrosis. While this drug is effective at alleviating symptoms resulting from the disease and improving overall survival, it's never led to complete hematological remissions. Imetelstat could thus become a major step forward in the treatment of this devastating blood-based disorder. 

Now what: Although the NEJM is a marquee medical journal, the fact is that these results were already known for the most part via the company's prior presentations at the last two American Society of Hematology meetings. So I'm not sure this huge upswing in share price is entirely warranted. 

Looking ahead, the real catalysts to be on the lookout for are the preliminary results from imetelstat's ongoing trial for relapsed/refractory myelofibrosis, and the start of the therapy's planned midstage trial in myelodysplastic syndromes. Both of these trials are being conducted by Geron's partner Janssen Biotech, a subsidiary of Johnson & Johnson.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
$1.31 (0.77%) $0.01
Johnson & Johnson Stock Quote
Johnson & Johnson
$173.52 (-1.13%) $-1.98
Novartis AG Stock Quote
Novartis AG
$88.68 (1.14%) $1.00
Incyte Corporation Stock Quote
Incyte Corporation
$74.11 (0.97%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.